Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

BRIEF-OncoQuest Signs Deal To Sell Drug Portfolio To Dual Industrial For $300 Mln

Published 2020-04-22, 12:55 p/m
Updated 2020-04-22, 01:00 p/m

April 22 (Reuters) - Quest Pharmatech Inc QPT.V :

* ONCOQUEST SIGNS A DEFINITIVE AGREEMENT TO SELL DRUG PORTFOLIO TO DUAL INDUSTRIAL FOR U.S. $300 MILLION AND COMMITMENT TO FUND THE OREGOVOMAB PHASE 3 CLINICAL TRIAL IN FRONTLINE OVARIAN CANCER

* QUEST PHARMATECH INC - DUAL WILL BE RESPONSIBLE FOR ALL CLINICAL AND NON-CLINICAL DEVELOPMENT EXPENSES FOR ONCOQUEST'S TECHNOLOGY

* QUEST PHARMATECH INC - DUAL WILL SECURE $75 MILLION FOR DEVELOPMENT WHICH IS EXPECTED NO LATER THAN JUNE 30, 2020 AND WILL TRIGGER FIRST CLOSING

* QUEST PHARMATECH - ONCOQUEST-DUAL DEAL IS IN EXCHANGE FOR U.S.$300 MILLION IN A COMBINATION OF DUAL COMMON STOCK AND DUAL PERPETUAL CONVERTIBLE BONDS

* QUEST PHARMATECH INC - AT EXECUTION DATE, ONCOQUEST SHALL RECEIVE U.S. $125 MILLION IN A PERPETUAL CONVERTIBLE BOND

* QUEST PHARMATECH - DUAL COMMITTED TO RETURNING 2.5 MILLION ONCOQUEST SHARES; AS A RESULT, QUEST'S OWNERSHIP INTEREST IN ONCOQUEST WILL RISE TO OVER 40%

* QUEST PHARMATECH INC - ONCOQUEST WILL HAVE RIGHT TO NOMINATE FOUR BOARD MEMBERS TO AN EIGHT-PERSON DUAL BOARD

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.